Validation of a New Low-Cost, Methanol-Based Fixative for Cervical Cytology and Human Papillomavirus Detection

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLEITE, Katia Ramos Moreira
dc.contributor.authorSILVA, Thais
dc.contributor.authorNAUM, Bruna
dc.contributor.authorCANAVEZ, Flavio
dc.contributor.authorCANAVEZ, Juliana
dc.contributor.authorPIMENTA, Ruan
dc.contributor.authorREIS, Sabrina
dc.contributor.authorCAMARA-LOPES, Luiz Heraldo
dc.date.accessioned2019-02-21T17:20:48Z
dc.date.available2019-02-21T17:20:48Z
dc.date.issued2018
dc.description.abstractObjective: To test the performance of a new fixative for pap smear collection for liquid-based cervical cytology, CellPreserv (R) and compare it with the commercially available, PreservCyt (R) used in the diagnosis and detection of human papillomavirus (HPV). Methods: Seven hundred twenty five women participated in this study after signing an informed consent. The specimens were collected using a traditional device, agitated in PBS, and equally divided in both fixatives. The slides were prepared routinely, stained by Papanicolaou, examined blindly by 2 cytologists, and reviewed by one cytopathologist. To search for HPV, 1,000 mu L from each fixative was taken and processed by polymerase chain reaction. Results: Considering the adequacy of samples, both fixatives had similar results - 0.33 and 0.32% of the cases unsatisfactory for PreservCyt (R) and CellPreserv (R), respectively. Considering the 701 satisfactory cases and comparing the new fixative to the traditional fixative, there was 99.3% concordance between both. The results regarding the HPV detection was 100% concordant between the 2 fixatives. Conclusion: The new methanol-based fixative, CellPreserv (R), is cheaper and equally efficient for treating cervical cancer screening and for HPV detection, and can be safely used by the health system prevailing in low-income countries. (C) 2018 S. Karger AG, Baseleng
dc.description.indexMEDLINEeng
dc.identifier.citationACTA CYTOLOGICA, v.62, n.5/Jun, p.393-396, 2018
dc.identifier.doi10.1159/000489873
dc.identifier.eissn1938-2650
dc.identifier.issn0001-5547
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/30770
dc.language.isoeng
dc.publisherKARGEReng
dc.relation.ispartofActa Cytologica
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright KARGEReng
dc.subjectLiquid-based cytologyeng
dc.subjectThinPrepeng
dc.subjectCellPreserveng
dc.subjectHuman papillomaviruseng
dc.subjectCervical intraepithelial neoplasiaeng
dc.subject.otherliquid-based cytologyeng
dc.subject.otherconventional cytologyeng
dc.subject.othercancereng
dc.subject.otherpopulationeng
dc.subject.othersurepatheng
dc.subject.wosPathologyeng
dc.titleValidation of a New Low-Cost, Methanol-Based Fixative for Cervical Cytology and Human Papillomavirus Detectioneng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalSILVA, Thais:Lab Genoa LPCM, Sao Paulo, Brazil
hcfmusp.author.externalNAUM, Bruna:Lab Genoa LPCM, Sao Paulo, Brazil
hcfmusp.author.externalCANAVEZ, Flavio:Lab Genoa LPCM, Sao Paulo, Brazil
hcfmusp.author.externalCANAVEZ, Juliana:Lab Genoa LPCM, Sao Paulo, Brazil
hcfmusp.author.externalCAMARA-LOPES, Luiz Heraldo:Lab Genoa LPCM, Sao Paulo, Brazil
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.contributor.author-fmusphcRUAN CESAR APARECIDO PIMENTA
hcfmusp.contributor.author-fmusphcSABRINA THALITA DOS REIS FARIA
hcfmusp.description.beginpage393
hcfmusp.description.endpage396
hcfmusp.description.issue5/Jun
hcfmusp.description.volume62
hcfmusp.origemWOS
hcfmusp.origem.pubmed29913440
hcfmusp.origem.scopus2-s2.0-85048852831
hcfmusp.origem.wosWOS:000454161600011
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAlbrow R, 2012, CANCER CYTOPATHOL, V120, P87, DOI 10.1002/cncy.20203eng
hcfmusp.relation.referenceBeal CM, 2014, SALUD PUBLICA MEXICO, V56, P492eng
hcfmusp.relation.referenceBeerman H, 2009, GYNECOL ONCOL, V112, P572, DOI 10.1016/j.ygyno.2008.12.012eng
hcfmusp.relation.referenceColgan TJ, 2004, CANCER CYTOPATHOL, V102, P362, DOI 10.1002/cncr.20656eng
hcfmusp.relation.referenceCox JT, 2009, J CLIN VIROL, V45, pS3, DOI 10.1016/S1386-6532(09)70002-2eng
hcfmusp.relation.referenceFremont-Smith M, 2004, CANCER CYTOPATHOL, V102, P269, DOI 10.1002/cncr.30599eng
hcfmusp.relation.referenceKarnon J, 2004, HEALTH TECHNOL ASSES, V8, P1eng
hcfmusp.relation.referenceLongatto A, 2015, ACTA CYTOL, V59, P273, DOI 10.1159/000435801eng
hcfmusp.relation.referenceNayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521eng
hcfmusp.relation.referencePayne N, 2000, Health Technol Assess, V4, P1eng
hcfmusp.relation.referenceQu WM, 1997, J CLIN MICROBIOL, V35, P1304eng
hcfmusp.relation.referenceROZEMEIJER K, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/BMJ.J504eng
hcfmusp.relation.referenceRozemeijer K, 2016, CANCER CAUSE CONTROL, V27, P15, DOI 10.1007/s10552-015-0678-1eng
hcfmusp.relation.referenceSiebers AG, 2009, JAMA-J AM MED ASSOC, V302, P1757, DOI 10.1001/jama.2009.1569eng
hcfmusp.relation.referenceSimion N, 2014, ROM J MORPHOL EMBRYO, V55, P1331eng
hcfmusp.relation.referenceStoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500eng
hcfmusp.relation.referenceWeintraub J, 2000, DIAGN CYTOPATHOL, V22, P52, DOI 10.1002/(SICI)1097-0339(200001)22:1<52::AID-DC14>3.3.CO;2-Reng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublication622b95d5-7600-4a54-a1bc-204957b81985
relation.isAuthorOfPublication73be4bca-f8ad-443f-90b5-10e2e62b1e27
relation.isAuthorOfPublication.latestForDiscovery23772d3b-0da7-472f-8d56-e6312dbf95c1
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03